Search research articles
Contact Us
Filters
Showing results (61-70 of 84) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 12, 1999
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
L D Piro, C A White, A J Grillo-López, et al.
Experimental Eye Research
|
November 18, 2005
The pharmacokinetics of rituximab following an intravitreal injection
Hyuncheol Kim, Karl G Csaky, Chi-Chao Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
G A Wiseman, C A White, T E Witzig, et al.
Biorxiv : the Preprint Server for Biology
|
May 7, 2024
Development of Allosteric Small Molecule APOBEC3B Inhibitors from <i>In Silico</i> Screening
Katherine F M Jones, Özlem Demir, Mackenzie K Wyllie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab
T A Davis, C A White, A J Grillo-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 1999
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
T E Witzig, C A White, G A Wiseman, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
Gregory A Wiseman, Bryan R Leigh, William D Erwin, et al.
Archivos De Cardiologia De Mexico
|
September 11, 2017
[Impact of rotational coronary angiography in the amount of iodinated contrast and the exposure to ionising radiations in patients undergoing invasive coronary procedures: A systematic review and meta-analysis]
Diego Fernández-Rodríguez, Leydimar Anmad Shihadeh, José L Martos-Maine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
Thomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2023
Fragment-Based NMR Screening of the BPTF PHD Finger Methyl Lysine Reader Leads to the First Small-Molecule Inhibitors
Caroline R Buchholz, Molly S Sneddon, Joseph E McPherson, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 84) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 12, 1999
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
L D Piro, C A White, A J Grillo-López, et al.
Experimental Eye Research
|
November 18, 2005
The pharmacokinetics of rituximab following an intravitreal injection
Hyuncheol Kim, Karl G Csaky, Chi-Chao Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
G A Wiseman, C A White, T E Witzig, et al.
Biorxiv : the Preprint Server for Biology
|
May 7, 2024
Development of Allosteric Small Molecule APOBEC3B Inhibitors from <i>In Silico</i> Screening
Katherine F M Jones, Özlem Demir, Mackenzie K Wyllie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab
T A Davis, C A White, A J Grillo-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 1999
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
T E Witzig, C A White, G A Wiseman, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
Gregory A Wiseman, Bryan R Leigh, William D Erwin, et al.
Archivos De Cardiologia De Mexico
|
September 11, 2017
[Impact of rotational coronary angiography in the amount of iodinated contrast and the exposure to ionising radiations in patients undergoing invasive coronary procedures: A systematic review and meta-analysis]
Diego Fernández-Rodríguez, Leydimar Anmad Shihadeh, José L Martos-Maine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
Thomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2023
Fragment-Based NMR Screening of the BPTF PHD Finger Methyl Lysine Reader Leads to the First Small-Molecule Inhibitors
Caroline R Buchholz, Molly S Sneddon, Joseph E McPherson, et al.
Page
of 9